Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 1
1949 1
1950 2
1958 2
1960 3
1964 2
1965 1
1966 2
1967 1
1968 2
1970 2
1974 1
1975 1
1978 3
1979 1
1980 2
1985 2
1986 4
1987 1
1988 2
1989 1
1990 4
1991 3
1992 8
1993 17
1994 11
1995 4
1996 7
1997 11
1998 12
1999 14
2000 17
2001 18
2002 13
2003 13
2004 17
2005 26
2006 26
2007 29
2008 37
2009 36
2010 56
2011 76
2012 71
2013 95
2014 107
2015 110
2016 116
2017 123
2018 140
2019 139
2020 156
2021 166
2022 166
2023 181
2024 44

Text availability

Article attribute

Article type

Publication date

Search Results

1,905 results

Results by year

Filters applied: . Clear all
Page 1
Survival with Cemiplimab in Recurrent Cervical Cancer.
Tewari KS, Monk BJ, Vergote I, Miller A, de Melo AC, Kim HS, Kim YM, Lisyanskaya A, Samouëlian V, Lorusso D, Damian F, Chang CL, Gotovkin EA, Takahashi S, Ramone D, Pikiel J, Maćkowiak-Matejczyk B, Guerra Alía EM, Colombo N, Makarova Y, Rischin D, Lheureux S, Hasegawa K, Fujiwara K, Li J, Jamil S, Jankovic V, Chen CI, Seebach F, Weinreich DM, Yancopoulos GD, Lowy I, Mathias M, Fury MG, Oaknin A; Investigators for GOG Protocol 3016 and ENGOT Protocol En-Cx9. Tewari KS, et al. Among authors: de melo ac. N Engl J Med. 2022 Feb 10;386(6):544-555. doi: 10.1056/NEJMoa2112187. N Engl J Med. 2022. PMID: 35139273 Clinical Trial.
Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial.
Westin SN, Moore K, Chon HS, Lee JY, Thomes Pepin J, Sundborg M, Shai A, de la Garza J, Nishio S, Gold MA, Wang K, McIntyre K, Tillmanns TD, Blank SV, Liu JH, McCollum M, Contreras Mejia F, Nishikawa T, Pennington K, Novak Z, De Melo AC, Sehouli J, Klasa-Mazurkiewicz D, Papadimitriou C, Gil-Martin M, Brasiuniene B, Donnelly C, Del Rosario PM, Liu X, Van Nieuwenhuysen E; DUO-E Investigators. Westin SN, et al. Among authors: de melo ac. J Clin Oncol. 2024 Jan 20;42(3):283-299. doi: 10.1200/JCO.23.02132. Epub 2023 Oct 21. J Clin Oncol. 2024. PMID: 37864337 Free PMC article. Clinical Trial.
Frailty syndrome and risks for falling in the elderly community.
Taguchi CK, Menezes PL, Melo ACS, Santana LS, Conceição WRS, Souza GF, Araújo BCL, Silva ARD. Taguchi CK, et al. Among authors: melo acs. Codas. 2022 Aug 8;34(6):e20210025. doi: 10.1590/2317-1782/20212021025pt. eCollection 2022. Codas. 2022. PMID: 35946721 Free PMC article.
Platynosomum illiciens.
Pinto HA, Melo AL, Mati VLT. Pinto HA, et al. Among authors: melo al. Trends Parasitol. 2022 Feb;38(2):188-189. doi: 10.1016/j.pt.2021.08.004. Epub 2021 Sep 1. Trends Parasitol. 2022. PMID: 34481739 No abstract available.
The Biofilms Structural Database.
Magalhães RP, Vieira TF, Fernandes HS, Melo A, Simões M, Sousa SF. Magalhães RP, et al. Among authors: melo a. Trends Biotechnol. 2020 Sep;38(9):937-940. doi: 10.1016/j.tibtech.2020.04.002. Epub 2020 May 5. Trends Biotechnol. 2020. PMID: 32386874 Review.
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial.
Kristeleit R, Lisyanskaya A, Fedenko A, Dvorkin M, de Melo AC, Shparyk Y, Rakhmatullina I, Bondarenko I, Colombo N, Svintsitskiy V, Biela L, Nechaeva M, Lorusso D, Scambia G, Cibula D, Póka R, Oaknin A, Safra T, Mackowiak-Matejczyk B, Ma L, Thomas D, Lin KK, McLachlan K, Goble S, Oza AM. Kristeleit R, et al. Among authors: de melo ac. Lancet Oncol. 2022 Apr;23(4):465-478. doi: 10.1016/S1470-2045(22)00122-X. Epub 2022 Mar 14. Lancet Oncol. 2022. PMID: 35298906 Clinical Trial.
Diagnostic imaging in bronchial atresia.
de Melo ASA. de Melo ASA. Radiol Bras. 2021 Mar-Apr;54(2):V. doi: 10.1590/0100-3984.2021.54.2e1. Radiol Bras. 2021. PMID: 33854270 Free PMC article. No abstract available.
Oxidative Stress and Inflammation in Acute and Chronic Lung Injuries.
Bezerra FS, Lanzetti M, Nesi RT, Nagato AC, Silva CPE, Kennedy-Feitosa E, Melo AC, Cattani-Cavalieri I, Porto LC, Valenca SS. Bezerra FS, et al. Among authors: melo ac. Antioxidants (Basel). 2023 Feb 21;12(3):548. doi: 10.3390/antiox12030548. Antioxidants (Basel). 2023. PMID: 36978796 Free PMC article. Review.
1,905 results